EUVIMEDEUVIMED entdecken
Crossref

Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis

Vladimir Aladinskiy iD, Chris Kruse, Luoheng Qin, Eugene Babin, Yaya Fan, Georgiy Andreev, Heng Zhao, Yanyun Fu, Man Zhang, Yan Ivanenkov iD, Alex Aliper iD, Alex Zhavoronkov iD und 1 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Vladimir Aladinskiy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine AI Ltd., Level 6, Unit 08, Block A, IRENA HQ Building Masdar City, Abu Dhabi 145748, United Arab Emirates. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traf2- and Nck-interacting kinase (TNIK) has been identified as a promising therapeutic target for the treatment of fibrosis-driven diseases. Utilizing a structure-based drug design workflow, we developed a series of potent TNIK inhibitors that modulate the conformation of the gatekeeper Met105 side chain and access the TNIK back pocket. The lead optimization efforts culminated in the discovery of the recently reported compound 4 (INS018_055), a novel TNIK inhibitor. This molecule demonstrated excellent activity in both enzymatic and cell-based assays, along with high selectivity in a kinome panel. Further, in vitro and in vivo preclinical studies revealed favorable in vitro and in vivo DMPK properties. Results from multiple cell-based and animal models proved that compound 4 exhibits considerable antifibrotic and anti-inflammatory efficacy. Currently, phase II clinical trials of compound 4 are underway for the treatment of idiopathic pulmonary fibrosis (IPF).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisProtein Kinase InhibitorsHumansAnimalsStructure-Activity RelationshipDrug DiscoveryMiceImidazolesRatsProtein Serine-Threonine Kinases

Substanzen

Protein Kinase InhibitorsTNIK protein, humanImidazolesProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Insilico Medicine AI Ltd., Level 6, Unit 08, Block A, IRENA HQ Building Masdar City, Abu Dhabi 145748, United Arab Emirates.
  • Insilico Medicine Hong Kong Ltd., Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories 999077, Hong Kong.
  • Insilico Medicine Shanghai Ltd., 9F, Chamtime Plaza Block C, Lane 2889, Jinke Road, Pudong New Area, Shanghai 200120, China.
  • Insilico Medicine Canada Inc, 1250 René-Lévesque Ouest, Suite 3710, Montréal, Québec H3B 4W8, Canada.

ORCID-Profile: Vladimir Aladinskiy, Yan Ivanenkov, Alex Aliper, Alex Zhavoronkov, Feng Ren

Zitieren

APA

Aladinskiy, V., Kruse, C., Qin, L., Babin, E., Fan, Y., Andreev, G., Zhao, H., Fu, Y., Zhang, M., Ivanenkov, Y., Aliper, A., Zhavoronkov, A., & Ren, F. (2024). Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01580

Vancouver

Aladinskiy V, Kruse C, Qin L, Babin E, Fan Y, Andreev G, et al. Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01580

BibTeX
@article{Aladinskiy2024,
  author = {Aladinskiy, Vladimir and Kruse, Chris and Qin, Luoheng and Babin, Eugene and Fan, Yaya and Andreev, Georgiy and Zhao, Heng and Fu, Yanyun and Zhang, Man and Ivanenkov, Yan and Aliper, Alex and Zhavoronkov, Alex and Ren, Feng},
  title = {Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01580}
}
Kostenlos starten →